AlphaCrest Capital Management LLC purchased a new stake in Personalis, Inc. (NASDAQ:PSNL) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 20,400 shares of the company’s stock, valued at approximately $516,000.
Other hedge funds also recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its holdings in shares of Personalis by 7.9% during the second quarter. Legal & General Group Plc now owns 7,384 shares of the company’s stock worth $186,000 after purchasing an additional 539 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Personalis by 38.2% in the second quarter. Ameritas Investment Partners Inc. now owns 2,791 shares of the company’s stock valued at $71,000 after purchasing an additional 771 shares during the last quarter. Rhumbline Advisers grew its position in Personalis by 3.3% during the 1st quarter. Rhumbline Advisers now owns 25,554 shares of the company’s stock worth $629,000 after purchasing an additional 818 shares during the period. Royal Bank of Canada grew its holdings in Personalis by 1.2% during the first quarter. Royal Bank of Canada now owns 82,096 shares of the company’s stock worth $2,020,000 after acquiring an additional 945 shares during the period. Finally, Advisor Group Holdings Inc. raised its position in Personalis by 79.1% during the second quarter. Advisor Group Holdings Inc. now owns 2,778 shares of the company’s stock valued at $71,000 after acquiring an additional 1,227 shares in the last quarter. Institutional investors own 68.57% of the company’s stock.
In other Personalis news, CFO Aaron Tachibana sold 3,152 shares of the company’s stock in a transaction dated Friday, September 17th. The stock was sold at an average price of $21.25, for a total transaction of $66,980.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Richard Chen sold 4,436 shares of the business’s stock in a transaction dated Friday, August 6th. The stock was sold at an average price of $21.22, for a total value of $94,131.92. The disclosure for this sale can be found here. Insiders have sold 12,787 shares of company stock worth $274,345 over the last 90 days. 7.50% of the stock is owned by insiders.
Personalis (NASDAQ:PSNL) last posted its earnings results on Wednesday, August 4th. The company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.05. The company had revenue of $21.67 million for the quarter, compared to analysts’ expectations of $21.15 million. Personalis had a negative net margin of 60.87% and a negative return on equity of 18.51%. Analysts expect that Personalis, Inc. will post -1.53 EPS for the current fiscal year.
A number of research analysts have weighed in on the stock. Citigroup cut their price objective on shares of Personalis from $37.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, August 5th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Personalis in a research note on Thursday, September 23rd. Needham & Company LLC decreased their target price on Personalis from $33.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, September 20th. TheStreet lowered shares of Personalis from a “c-” rating to a “d” rating in a research report on Thursday, July 22nd. Finally, BTIG Research reduced their target price on Personalis from $35.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, September 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $36.00.
Personalis, Inc engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
Further Reading: How is net asset value different from market price?
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.